Several lines of evidence from in vitro and in vivo studies suggest that specific micronutrients may have beneficial effects in age-related macular degeneration (AMD). Such effects appear to be complex and may include filtering short wavelength light and attenuating oxidative and inflammatory damage as well as other structural and physiological factors. There is clinical evidence for potential benefits from vitamin C, β-carotene, vitamin E and zinc, as well as emerging epidemiological and clinical data for the carotenoids lutein and zeaxanthin and for omega-3 fatty acids. A survey of the literature suggests that some specific micronutrients may be of value in treating or preventing AMD, but further prospective studies are needed to further identify and characterize their effects and place in therapy.

Keywords:
Macular degeneration, Nutrition, Micronutrients, Vitamin C, Vitamin E, Zinc, Lutein, Zeaxanthin, Omega-3, β-Carotene
1.
Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–1436.
2.
Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L: Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liees a l’Age. Arch Ophthalmol 1999;117:1384–1390.
3.
van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT: Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005;294:3101–3107.
4.
Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ: Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 2002;325:11.
5.
Christen WG, Ajani UA, Glynn RJ, Manson JE, Schaumberg DA, Chew EC, Buring JE, Hennekens CH: Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. Am J Epidemiol 1999;149:476–484.
6.
Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group. Arch Ophthalmol 1993;111:104–109.
7.
West S, Vitale S, Hallfrisch J, Muñoz B, Muller D, Bressler S, Bressler NM: Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol 1994;112:222–227.
8.
VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M: Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 1998;148:204–214.
9.
Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P: Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008;115:334–341.
10.
Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT, Lawrence A. Yannuzzi LA, Willett W: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272:1413–1420.
11.
Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch W: Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest Ophthalmol Vis Sci 2006;47:2329–2335.
12.
Gale CR, Hall NF, Phillips DI, Martyn CN: Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2003;44:2461–2465.
13.
Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216–230.
14.
Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB, Mares JA; CAREDS Research Study Group: Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women’s Health Initiative. Arch Ophthalmol 2006;124:1151–1162.
15.
Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhöfer G, Schmidt-Erfurth U, Schmetterer L: Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:8174- 8178.
16.
Koh HH, Murray IJ, Nolan D, Carden D, Feather J, Beatty S: Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp Eye Res 2004;79:21–27.
17.
Seddon JM, George S, Rosner B: Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006;124:995–1001.
18.
SanGiovanni JP, Chew EY, Agrón E, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Klein R, Sperduto RD; Age-Related Eye Disease Study Research Group: The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol 2008;126:1274–1279.
19.
SanGiovanni JP, Agron E, Clemons TE, Chew EY: Omega-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration. Arch Ophthalmol 2009;127:110–112.
20.
Chong EW-T, Kreis AJ, Wong TY, Simpson JA, Guymer RH: Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration. A systematic review and meta-analysis. Arch Ophthalmol 2008;126:826–833.
21.
Chong EW-T, Robman LD, Simpson JA, Hodge AM, Aung KZ, Dolphin TK, English DR, Giles GG, Guymer RH: Fat consumption and its association with age-related macular degeneration. Arch Ophthalmol 2009;127:674–680.
22.
Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P: Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol 2006;124:981–986.
23.
Augood C, Chakravarthy U, Young I, Vioque J, de Jong PT, Bentham G, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, Fletcher AE: Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr 2008;88:398–406.
24.
Cho E, Hung S, Willett WC, Spiegelman D, Rimm EB, Seddon JM, Colditz GA, Hankinson SE: Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 2001;73:209–218.
25.
Christen WG, Schaumberg DA, Glynn RJ, Buring JE: Dietary omega-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol 2011;129:921–929.
26.
Swenor BK, Bressler S, Caulfield L, West SK: The impact of fish and shellfish consumption on age-related macular degeneration. Ophthalmology 2010;117:2395–2401.
27.
Merle B, Delyfer MN, Korobelnik JF, Rougier MB, Colin J, Malet F, Féart C, Le Goff M, Dartigues JF, Barberger-Gateau P, Delcourt C: Dietary omega-3 fatty acids and the risk for age-related maculopathy: the Alienor Study. Invest Ophthalmol Vis Sci 2011;52:6004–6011.
28.
Delcourt C, Carriere I, Cristol JP, Lacroux A, Gerber M: Dietary fat and the risk of age-related maculopathy: the POLANUT study. Eur J Clin Nutr 2007;61:1341–1344.
29.
Carriere I, Delcourt C, Lacroux A Gerber M: Nutrient intake in an elderly population in southern France (POLANUT): deficiency in some vitamins, minerals and omega-3 PUFA. Int J Vitam Nutr Res 2007;77:57–65.
30.
Feart C, Jutand MA, Larrieu S, Letenneur L, Delcourt C, Combe N, Barberger-Gateau P: Energy, macronutrient and fatty acid intake of French elderly community dwellers and association with socio-demographic characteristics: data from the Bordeaux sample of the Three-City Study. Br J Nutr 2007;98:1046–1057.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.